肝细胞癌死亡率的全球趋势与预测
基于世界卫生组织1990-2014年死亡证明数据,分析16个欧洲国家、5个美洲国家及6个其他国家的肝细胞癌死亡率趋势,并预测欧盟、美国和日本至2020年的趋势。欧洲男性死亡率近十年稳定在3.5/10万,美国2002-2012年上升35%至2012年男性3.1/10万,东亚下降但仍达10-24/10万,日本预测2020年降至男性5.4/10万。
要点
- 欧洲男性肝细胞癌死亡率近十年稳定在3.5/10万,北欧和中欧上升,南欧下降。
- 美国肝细胞癌死亡率2002-2012年上升35%,2012年男性达3.1/10万,预测至2020年稳定。
- 东亚死亡率下降但仍达10-24/10万,日本预测2020年男性降至5.4/10万。
核心结论
- 乙肝和丙肝病毒感染的控制促成了东亚和南欧肝细胞癌死亡率的下降。
- 其他地区的不利趋势可归因于1960年代和1980年代的丙肝(及乙肝)流行、饮酒、超重/肥胖增加和糖尿病。
- 肝硬化管理、肝细胞癌诊断和治疗的改善也影响全球死亡率趋势。
研究设计与样本
- 分析世界卫生组织数据库1990-2014年肝细胞癌死亡证明数据。
- 纳入16个欧洲国家、5个美洲国家、6个其他国家及整个欧盟。
主要发现
- 欧洲男性死亡率近十年稳定在3.5/10万,北欧和中欧上升,南欧下降。
- 美国肝细胞癌死亡率2002-2012年上升35%,2012年男性达3.1/10万,预测至2020年稳定。
- 东亚死亡率下降但仍达10-24/10万,日本预测2020年男性降至5.4/10万。
- 年轻人群趋势有利,中年人群除东亚外趋势不利。
- 多数地区女性死亡率比男性低3-5倍,但趋势相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Trends in hepatocellular carcinoma (HCC) mortality rates have increased over recent decades in most countries. It is also the third cause of cancer death worldwide. The aim of this study is to update global trends in HCC mortality to 2014, and predict trends in rates in the EU, USA and Japan to 2020. METHODS: Death certification data for HCC over the 1990-2014 period from the World Health Organization database were analyzed. Sixteen European, five American countries, and six other countries worldwide were included, as well as the EU as a whole. RESULTS: In European men, mortality rates were stable during the last decade (3.5/100,000). HCC mortality increased in Northern and Central Europe, and decreased in Southern Europe. In the USA, HCC mortality increased by 35% between 2002 and 2012, reaching 3.1/100,000 men in 2012; it is predicted to remain stable to 2020. Reduced mortality rates were observed in East Asia, although they remained around 10-24/100,000 men. In Japan, HCC mortality is predicted to decrease (5.4/100,000 men in 2020). Trends were favorable in the young, but unfavorable in middle aged, except in East Asia. Mortality rates were 3- to 5-fold lower in women than men in most regions, but trends were similar. CONCLUSIONS: Control of hepatitis B (HBV) and hepatitis C virus (HCV) infections has contributed to the decrease in HCC-related mortality in East Asia and Southern Europe. Unfavorable trends in other regions can be attributed to HCV (and HBV) epidemics in the 1960s and 1980s, alcohol consumption, increased overweight/obesity, and diabetes. Better management of cirrhosis, HCC diagnosis and treatment are also influencing the mortality trends worldwide. LAY SUMMARY: Mortality rates due to HCC have increased in many countries over recent decades. In this study, we updated worldwide mortality trends for HCC from 1990 to 2014, and predicted trends for some countries to 2020. We observed unfavorable trends in Northern and Central Europe, North and Latin America. East Asia showed an improvement, however mortality rates in this region were 2- to 5-fold higher than in most European countries and the Americas. Steady declines to 2020 are predicted for East Asia but not for Europe and the Americas.
引用
- Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017. PMID: 28336466. doi:10.1016/j.jhep.2017.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。